BMEA — Biomea Fusion, Inc.
Biomea Fusion, Inc., a biopharmaceutical company, focuses on the discovery and development of covalent small molecule drugs to treat patients with genetically defined cancers and metabolic diseases. Its lead product candidate is BMF-219, an orally bioavailable, potent, and selective covalent inhibitor of menin, a transcriptional regulator in oncogenic signaling in multiple cancers. The company was incorporated in 2017 and is headquartered in Redwood City, California.
Company profile
- Sector: Healthcare
- Industry: Biotechnology
- Country: US
- Exchange: NASDAQ
- Employees: 79
- Website: https://biomeafusion.com
Latest SEC filings for BMEA
- 8-K — 2026-10-14
- 424B5 — 2026-09-22
- 424B5 — 2026-09-22
- 8-K — 2026-09-22
- 10-Q — 2026-08-05
- 8-K — 2026-08-05
- 8-K — 2026-06-11
- 8-K — 2026-05-11
- 10-Q — 2026-05-11
- 8-K — 2026-04-28
Latest BMEA news
- — Biomea Fusion, Inc. (BMEA) Discusses BMF-650 Phase I Topline Results and Potential for Separating GI Side Effects from Weight Loss Transcript (seekingalpha.com)
- — Biomea Fusion to Announce Phase I Results for BMF-650, Its Next-Generation Oral Small-Molecule GLP-1 Receptor Agonist
Educational tool only — not investment advice.